KR20240132477A - 중수소화 유기 화합물 및 이의 용도 - Google Patents

중수소화 유기 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20240132477A
KR20240132477A KR1020247025930A KR20247025930A KR20240132477A KR 20240132477 A KR20240132477 A KR 20240132477A KR 1020247025930 A KR1020247025930 A KR 1020247025930A KR 20247025930 A KR20247025930 A KR 20247025930A KR 20240132477 A KR20240132477 A KR 20240132477A
Authority
KR
South Korea
Prior art keywords
compound
disorder
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247025930A
Other languages
English (en)
Korean (ko)
Inventor
크리슈나 바도다리아
킴벌리 바노버
조르디 세라츠
비크람 수다르산
데이비드 가비
Original Assignee
엔그레일 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔그레일 테라퓨틱스, 인크. filed Critical 엔그레일 테라퓨틱스, 인크.
Publication of KR20240132477A publication Critical patent/KR20240132477A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247025930A 2022-01-03 2023-01-03 중수소화 유기 화합물 및 이의 용도 Pending KR20240132477A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263296137P 2022-01-03 2022-01-03
US63/296,137 2022-01-03
US202263314466P 2022-02-27 2022-02-27
US63/314,466 2022-02-27
US202263345002P 2022-05-23 2022-05-23
US63/345,002 2022-05-23
US202263394565P 2022-08-02 2022-08-02
US63/394,565 2022-08-02
US202263384988P 2022-11-25 2022-11-25
US63/384,988 2022-11-25
PCT/US2023/010055 WO2023130119A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
KR20240132477A true KR20240132477A (ko) 2024-09-03

Family

ID=87000385

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025930A Pending KR20240132477A (ko) 2022-01-03 2023-01-03 중수소화 유기 화합물 및 이의 용도

Country Status (10)

Country Link
US (1) US12606523B2 (https=)
EP (1) EP4460292A4 (https=)
JP (1) JP2025501411A (https=)
KR (1) KR20240132477A (https=)
AU (1) AU2023204433A1 (https=)
CA (1) CA3242755A1 (https=)
IL (1) IL313999A (https=)
MX (1) MX2024008371A (https=)
TW (1) TW202333671A (https=)
WO (1) WO2023130119A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)
WO2026011157A1 (en) 2024-07-05 2026-01-08 Engrail Therapeutics, Inc. Crystalline forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
TW212139B (https=) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
SK281042B6 (sk) 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法
US20190343827A1 (en) 2018-05-08 2019-11-14 Izumi Technology, Llc Deuterated analogs of tariquidar
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
US20210017160A1 (en) 2019-07-16 2021-01-21 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
TW202340145A (zh) 2022-01-03 2023-10-16 美商恩格瑞爾療法公司 氘化有機化合物及其用途
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)

Also Published As

Publication number Publication date
WO2023130119A1 (en) 2023-07-06
US20250011280A1 (en) 2025-01-09
EP4460292A1 (en) 2024-11-13
CA3242755A1 (en) 2023-07-06
MX2024008371A (es) 2024-12-06
JP2025501411A (ja) 2025-01-17
IL313999A (en) 2024-08-01
TW202333671A (zh) 2023-09-01
EP4460292A4 (en) 2025-07-16
US12606523B2 (en) 2026-04-21
AU2023204433A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
TWI888599B (zh) 取代哌啶化合物及其用途
US20190083420A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
US12606523B2 (en) Deuterated organic compounds and uses thereof
TWI543974B (zh) 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途
TW200404808A (en) Pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds therefor
US12365650B2 (en) Deuterated organic compounds and uses thereof
JP2003528096A (ja) デカヒドロ−イソキノリン
KR20240132476A (ko) 중수소화 유기 화합물 및 이의 용도
WO2022008383A1 (en) Isoquinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases
TWI644914B (zh) １，２，４－三唑并［４，３－ａ］吡啶化合物及其作為ＭＧＬＵＲ２受體之正向異位調節劑的用途
CN107108560B (zh) 化合物、组合物及其方法
US20240400571A1 (en) 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
EP4423094B1 (en) Rxfp1 modulators for the treatment of heart failure
CN121909189A (zh) 用于治疗精神疾病的吡咯并吡啶化合物
CN119384406A (zh) 化合物
CN118804746A (zh) 氘代有机化合物及其用途
CN118804910A (zh) 氘代有机化合物及其用途
CN117957222A (zh) 毒蕈碱受体4拮抗剂及使用方法
JP2014159375A (ja) アゼパン化合物
CN116693470A (zh) 组胺h3受体抑制剂及其医药用途
EA045865B1 (ru) Замещенные пиперидиновые соединения и их применение

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000